Portal Instruments Inc.
At-home, needle-free delivery system for biologics
This article was originally published in Start Up
Executive Summary
Patients who are required to self-inject biologics at home for managing chronic diseases like rheumatoid arthritis, multiple sclerosis, and diabetes might someday benefit from painless and needle-free drug delivery, thanks to a computer-controlled handheld device being developed by Portal Instruments Inc.
You may also be interested in...
Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval
Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.
Perrigo Plays Customary Card For Approval Of First OTC Ibuprofen-Acetaminophen Generic In US
First generic of Haleon Advil Dual Action approved as brand lost three-year market exclusivity and day after Perrigo announced end of phase 1 of turnaround strategy and start of starting phase 2.
Health Care Professionals Settle With FTC Over COVID-19 Claims For Direct Seller’s Supplements
Three distributors made claims doTerra's essential oils and supplements could treat or prevent COVID-19 in early 2022webinars. They also underscored medical expertise in recommending products.